The investor wants Perrigo to sell its Tysabri rights and this option will now be considered alongside a strategic review of all of its products.
Ireland-based Perrigo posted a net loss of $1.26bn, or $8.76 a share in its third quarter after impairment charges of almost US$1.7bn.
Stripping out the one-offs there was a profit per share US$1.65 per share, down from $1.76 last year.
Revenue rose slightly to $1.35bn.
Most of the impairments related to 2015’s acquisition of US$4.5bn purchase of Omega Pharma, where Perrigo expects to start legal action against the vendors.
Perrigo shareholders rejected a US$26bn takeover bid from rival pharma Mylan this time last year since when the share price has almost halved.
Today the shares were up 4% at US$87 valuing the group at just under US$12bn.
Story by ProactiveInvestors